Cargando…
Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial
Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized com...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598999/ https://www.ncbi.nlm.nih.gov/pubmed/36289668 http://dx.doi.org/10.3390/biomedicines10102404 |
_version_ | 1784816487273332736 |
---|---|
author | Shin, Jongbeom Lee, Jung-Hwan Park, Soo-Hyun Cha, Boram Kwon, Kye Sook Kim, Hyungkil Shin, Yong Woon |
author_facet | Shin, Jongbeom Lee, Jung-Hwan Park, Soo-Hyun Cha, Boram Kwon, Kye Sook Kim, Hyungkil Shin, Yong Woon |
author_sort | Shin, Jongbeom |
collection | PubMed |
description | Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized comparative study was performed with 48 patients. FMT material (60 g) was obtained from a healthy donor, frozen, and administered via endoscopy. The primary endpoint was 1-month decolonization, and secondary endpoints were 3-month decolonization and adverse events. Microbiota analysis of fecal samples was performed using 16S rRNA sequencing. Intention-to-treat analysis revealed overall negative conversion between the FMT and control groups at 1 (26% vs. 10%, p = 0.264) and 3 (52% vs. 24%, p = 0.049) months. The 1-month and 3-month CRE clearance did not differ significantly by group (36% vs. 10%, p = 0.341; and 71% vs. 30%, p = 0.095, respectively). Among patients with VRE, FMT was ineffective for 1-month or 3-month negative conversion (13% vs. 9%, p > 0.999; and 36% vs. 18%, p = 0.658, respectively) However, cumulative overall negative-conversion rate was significantly higher in the FMT group (p = 0.037). Enterococcus abundance in patients with VRE significantly decreased following FMT. FMT may be effective at decolonizing multidrug-resistant organisms in the intestinal tract. |
format | Online Article Text |
id | pubmed-9598999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95989992022-10-27 Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial Shin, Jongbeom Lee, Jung-Hwan Park, Soo-Hyun Cha, Boram Kwon, Kye Sook Kim, Hyungkil Shin, Yong Woon Biomedicines Article Fecal microbiota transplantation (FMT) could decolonize multidrug-resistant organisms. We investigated FMT effectiveness and safety in the eradication of carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) intestinal colonization. A prospective non-randomized comparative study was performed with 48 patients. FMT material (60 g) was obtained from a healthy donor, frozen, and administered via endoscopy. The primary endpoint was 1-month decolonization, and secondary endpoints were 3-month decolonization and adverse events. Microbiota analysis of fecal samples was performed using 16S rRNA sequencing. Intention-to-treat analysis revealed overall negative conversion between the FMT and control groups at 1 (26% vs. 10%, p = 0.264) and 3 (52% vs. 24%, p = 0.049) months. The 1-month and 3-month CRE clearance did not differ significantly by group (36% vs. 10%, p = 0.341; and 71% vs. 30%, p = 0.095, respectively). Among patients with VRE, FMT was ineffective for 1-month or 3-month negative conversion (13% vs. 9%, p > 0.999; and 36% vs. 18%, p = 0.658, respectively) However, cumulative overall negative-conversion rate was significantly higher in the FMT group (p = 0.037). Enterococcus abundance in patients with VRE significantly decreased following FMT. FMT may be effective at decolonizing multidrug-resistant organisms in the intestinal tract. MDPI 2022-09-26 /pmc/articles/PMC9598999/ /pubmed/36289668 http://dx.doi.org/10.3390/biomedicines10102404 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shin, Jongbeom Lee, Jung-Hwan Park, Soo-Hyun Cha, Boram Kwon, Kye Sook Kim, Hyungkil Shin, Yong Woon Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial |
title | Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial |
title_full | Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial |
title_fullStr | Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial |
title_full_unstemmed | Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial |
title_short | Efficacy and Safety of Fecal Microbiota Transplantation for Clearance of Multidrug-Resistant Organisms under Multiple Comorbidities: A Prospective Comparative Trial |
title_sort | efficacy and safety of fecal microbiota transplantation for clearance of multidrug-resistant organisms under multiple comorbidities: a prospective comparative trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598999/ https://www.ncbi.nlm.nih.gov/pubmed/36289668 http://dx.doi.org/10.3390/biomedicines10102404 |
work_keys_str_mv | AT shinjongbeom efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial AT leejunghwan efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial AT parksoohyun efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial AT chaboram efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial AT kwonkyesook efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial AT kimhyungkil efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial AT shinyongwoon efficacyandsafetyoffecalmicrobiotatransplantationforclearanceofmultidrugresistantorganismsundermultiplecomorbiditiesaprospectivecomparativetrial |